-
1
-
-
80051499508
-
-
Speedel Pharma Ltd, Basel, Switzerland
-
Speedel Pharma Ltd. Data on file. Basel, Switzerland.
-
Data on file
-
-
-
2
-
-
85036781142
-
-
Baltatu OC, Zaugg CE, Bader M, Dembowsky K. Additive kidney protective effects of an angiotensin receptor antagonist combined with the endothelin Type A receptor antagonist SPP301 in rat model of malignant hypertension. Poster presented at the ISH/ESH 2008 in Berlin (abstract # PS13/THU 16/S206). J Hypertension. 2008; 26 (Suppl 1).
-
Baltatu OC, Zaugg CE, Bader M, Dembowsky K. Additive kidney protective effects of an angiotensin receptor antagonist combined with the endothelin Type A receptor antagonist SPP301 in rat model of malignant hypertension. Poster presented at the ISH/ESH 2008 in Berlin (abstract # PS13/THU 16/S206). J Hypertension. 2008; 26 (Suppl 1).
-
-
-
-
3
-
-
85036778086
-
Integrated prediction of concentration-time profile in man following oral dosing
-
Poster presented at the, Budapest Hungary, September
-
Chou RC, Nick S, Morgenroth B, Lausecker B, Fischer G. Integrated prediction of concentration-time profile in man following oral dosing. Poster presented at the 6th European Congress of Pharmaceutical Sciences (EUFEPS), Budapest (Hungary), September 2000
-
(2000)
6th European Congress of Pharmaceutical Sciences (EUFEPS)
-
-
Chou, R.C.1
Nick, S.2
Morgenroth, B.3
Lausecker, B.4
Fischer, G.5
-
4
-
-
52149115147
-
Influence of food intake on the pharmacokinetics of avosentan in man
-
Dieterle W, Hengelage T. Influence of food intake on the pharmacokinetics of avosentan in man. Int J of Pharmacology and Therapeutics. 2008; 46: 453-458.
-
(2008)
Int J of Pharmacology and Therapeutics
, vol.46
, pp. 453-458
-
-
Dieterle, W.1
Hengelage, T.2
-
5
-
-
0347625574
-
A-selective endothelin receptor antagonist SPP301 in healthy human subjects
-
A-selective endothelin receptor antagonist SPP301 in healthy human subjects. J Clin Pharmacol. 2004; 44: 59-66.
-
(2004)
J Clin Pharmacol
, vol.44
, pp. 59-66
-
-
Dieterle, W.1
Mann, J.2
Kutz, K.3
-
8
-
-
85036786530
-
-
Jandeleit-Dahm K, Watson A, Soro-Paavonen A, Allen T, Thomas M, Schumacher C, Cooper M. The novel endothelin receptor A (ET-A) antagonist SPP301 attenuated albuminuria and renal structural injury in streptozotocin-induced diabetic apoE knockout mice. Poster presented at the ISH/ESH 2008 in Berlin (abstract # PS12/MON30/S194). J Hypertension. 2008; 26 (Suppl 1).
-
Jandeleit-Dahm K, Watson A, Soro-Paavonen A, Allen T, Thomas M, Schumacher C, Cooper M. The novel endothelin receptor A (ET-A) antagonist SPP301 attenuated albuminuria and renal structural injury in streptozotocin-induced diabetic apoE knockout mice. Poster presented at the ISH/ESH 2008 in Berlin (abstract # PS12/MON30/S194). J Hypertension. 2008; 26 (Suppl 1).
-
-
-
-
9
-
-
0038724606
-
Development of a liquid chromatographic/ tandem mass spectrometric assay for a new endothelin receptor antagonist, and its application to dog plasma samples generated after simultaneous i.v. and p.o. administration of the unlabeled and deuterium-labeled forms of this antagonist
-
Lausecker B, Fischer G. Development of a liquid chromatographic/ tandem mass spectrometric assay for a new endothelin receptor antagonist, and its application to dog plasma samples generated after simultaneous i.v. and p.o. administration of the unlabeled and deuterium-labeled forms of this antagonist. J Mass Spectrom. 2003; 38: 649-658.
-
(2003)
J Mass Spectrom
, vol.38
, pp. 649-658
-
-
Lausecker, B.1
Fischer, G.2
-
10
-
-
70449454368
-
-
Clinical Pharmacokinetics: Concepts and Application. 3rd ed, Lippincott, Williams & Wilkins;
-
Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Application. 3rd ed. Median, PA: Lippincott, Williams & Wilkins; 1995.
-
(1995)
Rowland M, Tozer TN
-
-
-
12
-
-
85036790971
-
-
A-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. Abstract presented at: 38th American Society of Nephrology Renal Week; Philadelphia; November 8-13, 2005. Abstract 550471.
-
A-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. Abstract presented at: 38th American Society of Nephrology Renal Week; Philadelphia; November 8-13, 2005. Abstract 550471.
-
-
-
-
13
-
-
0023859136
-
Anovel potent vasoconstrictor peptide produced by vascular endothelial cells
-
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. Anovel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332: 411-415.
-
(1988)
Nature
, vol.332
, pp. 411-415
-
-
Yanagisawa, M.1
Kurihara, H.2
Kimura, S.3
Tomobe, Y.4
Kobayashi, M.5
Mitsui, Y.6
|